Proteasomal activity is essential for eliminating excess proteins and, by counteracting protein production, establishes steady-state protein levels. The selective and often well-timed degradation of regulatory proteins by the proteasome orchestrates and modulates multiple biological processes such as gene transcription, metabolism, cell cycle progression and differentiation. [1] [2] Prolonged proteasome inhibition induces stress responses that initiate apoptosis via the intrinsic pathway. This is exploited clinically in the treatment of multiple myeloma with the proteasome inhibitor bortezomib ([(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid). Impaired proteasome activity results in the accumulation and/or transcriptional induction of BH3-only proteins such as Puma, Bim, Noxa or Bik. BH3-only proteins antagonise antiapoptotic Bcl-2 family members such as Bcl-2, Bcl-xL or Mcl-1 and/or can activate the proapoptotic members Bax and Bak. 3 Activated Bax and Bak form pores in the outer mitochondrial membrane, resulting in cytochrome c and Smac/Diablo release from the intermembrane space into the cytosol. This results in caspase-9 activation, inhibition of inhibitor of apoptosis (IAP) proteins, and subsequent apoptosis execution by effector caspases. 3 Proteasome inhibitors can evoke synergistic cell killing in combinations with other drugs that induce the intrinsic apoptosis pathway, such as cisplatin, doxorubicin, paclitaxel or histone deacetylase inhibitors, [4] [5] [6] [7] as well as with death receptor ligands activating the extrinsic pathway, such as tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas L. [8] [9] [10] [11] Although the molecular mechanisms bringing about the synergistic responses are still under investigation, evidence has accumulated that synergies may emanate from complementary sets of BH3-only proteins being induced or may result from more efficient formation of the death-inducing signalling complex (DISC) in response to death ligands.
Proteasome inhibition however may also promote more efficient apoptotic cell death through the stabilisation of proapoptotic proteins implicated in apoptosis execution. (N-(benzyloxycarbonyl)leucinylleucinylleucinal) was compared between parental and Bcl-2-overexpressing HeLa cells. Although p20 and p19 subunits could be detected, fully mature caspase-3 (p17) was not detected in HeLa-Bcl-2 cells. Pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp(O-methyl)-fluoromethylketone (zVAD-fmk) (50 mM) was used in combination with proteasome inhibitors in additional controls. b-Actin served as loading control. (e) Procaspase-3 processing in response to 100 nM bortezomib was analysed in parental and Bcl-2-overexpressing H460 cells. Arrows indicate p20, p19 and p17 subunits. a-Tubulin served as loading control. (f) As in (e), procaspase-3 processing in response to 100 nM bortezomib was analysed in parental or Bax/Bak-deficient mouse embryonic fibroblasts. Porin served as loading control. (g-i) Cell death in response to 100 nM bortezomib was determined by propidium iodide staining. Bcl-2 overexpression or Bax/Bak deficiency significantly reduced cell death. zVAD-fmk (50 mM) was added in additional control groups. Data are shown as means ± standard deviation (S.D.). Asterisks indicate significant reduction in cell death (Po0.05, Student's t-test). All experiments were preformed three times with comparable results Smac/Diablo and maybe also active caspases-9, -3 and -7 are subject to rapid IAP-mediated proteasomal degradation. [12] [13] Likewise, cytosolic cytochrome c is swiftly degraded, but can be stabilised by proteasome inhibition. 14 Here we investigated the consequences of proteasome inhibition on caspase activation and activity in human cancer cells. We show that in Bcl-2-overexpressing cancer cells refractory to mitochondrial permeabilisation, prolonged proteasome inhibition induced a mild, autophagy-dependent caspase-8 activation, which, upon antagonising XIAP, can be exploited to eliminate Bcl-2-overexpressing cells via the caspase-8/-3 axis.
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Results
Proteasome inhibition promotes residual processing of procaspase-3 in cells expressing high levels of Bcl-2. We investigated apoptosis signalling in response to proteasome inhibition by analysing the conversion of the caspase-3 zymogen into active subunits. Processing of procaspase-3 results in the generation of the small p12 and large p20 active subunits, with the latter being further processed to the p19 and then to the p17 fragment by rapid and slow autocatalytic steps, respectively. 15 Initially, we induced the intrinsic apoptosis pathway in HeLa cervical cancer cells by broad spectrum kinase inhibitor staurosporine (STS), N-glycosylation inhibitor tunicamycin, topoisomerase II inhibitor etoposide or proteasome inhibitor bortezomib. All drugs induced apoptosis execution, as noticed by procaspase-3 processing into the active caspase-3 p19/p17 subunits ( Figure 1a ). Particularly strong responses were observed upon STS and bortezomib treatment ( Figure 1a) . We then employed human cancer cells overexpressing Bcl-2 (Supplementary Figure 1) as model systems that are highly resistant to intrinsic apoptosis induction. Overexpression of Bcl-2 in HeLa cells fully abrogated procaspase-3 processing in response to all drugs, except bortezomib, which still evoked residual and incomplete procaspase-3 processing (Figure 1a , arrows). Processing was attenuated at the p20/p19 subunits ( Figure 1a, arrows) , indicating that the slow autocatalytic step towards the p17 subunit was suppressed. 15 Similar results were obtained when investigating other exposure durations or when employing proteasome inhibitors epoxomicin (N-acetyl-
Residual procaspase-3 processing was also observed in H460 non-small-cell lung cancer cells overexpressing Bcl-2 when exposed to bortezomib (Figure 1e ), but not when incubated with STS (not shown), and in Bax/Bak doubledeficient mouse embryonic fibroblasts (MEFs) (Figure 1f ). Bcl-2 overexpression or Bax/Bak deficiency reduced bortezomib-induced cell death, and a further reduction was observed when adding pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp(O-methyl)-fluoromethylketone (zVADfmk) (Figure 1g-i) . These results indicate that proteasome inhibition provokes a late and residual accumulation of incompletely processed caspase-3 as well as limited amounts of cell death in cells that otherwise seem refractory to intrinsic apoptosis. In the following, we therefore characterised the mode of caspase activation through proteasome inhibition in mitochondrial outer membrane permeabilisation (MOMP)-impaired cells. Owing to its high apoptotic potency (Figure 1a ), we used STS in control groups as a model for classical MOMP-dependent apoptosis, but avoided treatment durations that result in secondary cell death arising from prolonged broad range kinase inhibition 16 (Supplementary Figure 2) .
Proteasome inhibition induces low levels of DEVDase activity in Bcl-2-overexpressing cells. To investigate whether the detected caspase processing resulted in any noticeable activity, we next measured DEVD substrate cleavage by Fö rster resonance energy transfer (FRET) disruption. 17 In the FRET substrate, a caspase cleavage site (DEVD) links donor and acceptor fluorophores (cyan and yellow fluorescent protein (CFP, YFP)), and CFP fluorescence increases upon substrate cleavage (Figure 2a) . The DEVD sequence is optimally cleaved by caspase-3 and -7, but can also be cleaved by initiator caspase-8. 18 As the FRET probe is a soluble cytosolic protein, the analysis is restricted to non-permeabilised cells. In parental HeLa cells, bortezomib and STS resulted in FRET probe cleavage in nearly all cells (Figure 2b ). In cells (Figure 2e ), indicative of a caspase-3-dependent rapid probe cleavage as described in response to other drugs previously. 17 In contrast, scatter plots of HeLa-Bcl-2 cells showed a significant number of cells with submaximal probe cleavage, that is, they were positioned in-between populations with intact and cleaved probe (Figure 2f) . A ratiometric CFP/FRET display likewise indicated that parental cells displayed with intact or cleaved probe, whereas in HeLa-Bcl-2 cells the two populations could not be separated (Figure 2g and h). These results therefore show that proteasome inhibition induces low DEVDase activities in cells that otherwise do not respond to intrinsic apoptosis initiation.
Time-lapse analysis of DEVDase activation and activity induced by proteasome inhibition. We next employed FRET-based single-cell time-lapse imaging to determine the kinetics and timings of DEVDase activation. Most cells responded with DEVDase activation within 72 h of bortezomib addition, independent of Bcl-2 overexpression (Figure 3a ). However, DEVDase activity in HeLa Bcl-2 cells started later than in parental cells (14 ± 3.2 h; mean ± S.E.M.) ( Figure 3b ). Once initiated, probe cleavage proceeded rapidly in parental HeLa cells (14.7±1.0 min; mean ± S.E.M.), indicating a swift activation of effector caspases ( Figure 3c ). Similar cleavage durations were measured in response to STS (11.5±0.7 min; mean± S.E.M.; n ¼ 21 cells analysed from three experiments), corresponding to previously published data. 19 In contrast, probe cleavage in HeLa-Bcl-2 cells proceeded significantly slower (81.3±13.4 min; mean±S.E.M.) ( Figure 3c ). In many of these cells, the cleavage process might not have reached completion before termination of image acquisition as many cells detached and left the focal plane late during substrate cleavage. We therefore additionally determined the slopes of the FRET disruption traces to measure DEVDase activity, and found a significant reduction in HeLa-Bcl-2 cells (Figure 3d ). Floating cells, analysed by western blotting for probe cleavage, provided additional evidence for submaximal substrate cleavage (Supplementary Figure 3) .
We also loaded cells with tetramethylrhodamine-methylester (TMRM) to monitor changes in mitochondrial membrane potentials (DC M ). As DC M rapidly drops upon cytochrome c release at standard experimental conditions, TMRM was used as a surrogate marker for MOMP. As expected, in HeLa cells treated with STS, DEVDase activity was exclusively detected subsequent to DC M depolarisation (3.2 ± 0.4 min lag time; mean ± S.E.M.), corresponding to earlier reports. 19 Similarly, proteasome inhibition resulted in DEVDase activity subsequent to DC M depolarisation in most cells (Figure 3e a substrate preferred by caspase-3, accumulated strongly in parental cells, whereas in HeLa-Bcl-2 cells, only a mild and late increase was detected (Figure 3i ). These data therefore indicate that proteasome inhibition can result in a mild, submaximal activation of DEVDases independent of MOMP. timed so that protein were maximally depleted before residual caspase processing set in (see Materials and Methods and Supplementary Figure 8) . As caspase-3 is the most potent DEVDase, we first depleted HeLa-Bcl-2 cells of procaspase-3 ( Figure 4a,  Supplementary Figure 8A) . Interestingly, DEVDase activity arising from bortezomib exposure was not reduced (Figure 4b) , and time-lapse imaging indicated that the frequency of DEVDase activation was not notably affected (see Figure 5f ). In control experiments, the depletion of procaspase-3 however was sufficient to impair TRAIL/ cycloheximide (CHX)-induced apoptosis in HeLa cells (Supplementary Figure 4) . We next also employed caspase-3-deficient MCF-7 cells overexpressing Bcl-2. Consistent with results shown for HeLa and H460 cells, MCF-7-Bcl-2 but not parental MCF-7 cells were refractory to STS-induced apoptosis and DEVD probe cleavage (Supplementary Figure 5) . Depleting MCF-7-Bcl-2 cells of procaspase-7 eliminated all DEVD-preferring caspases (Figure 4c , Supplementary Figure 8B ). Interestingly, independent of caspase-7, proteasome inhibition resulted in cells localising across a continuous spectrum from intact to cleaved FRET substrate (Figure 4d ). These data therefore indicate that FRET probe cleavage apparently does not depend on a significant activation of the major DEVDases caspase-3 or -7. MOMP-independent DEVDase activity arises from FADDdependent caspase-8 activation. As caspase-8 is known to possess substantial DEVDase activity, 18 we next tested its involvement in generating the caspase activity we observed. Procaspase-8 was processed in response to bortezomib in HeLa cells (Figure 5a ) at times correlating with caspase-3 activation (Figure 1b) , as would be expected from caspase-3-dependent feedback processing. In HeLa-Bcl-2 cells, only low amounts of cleaved caspase-8 were detected (Figure 5b ). The cleavage of Bid, a physiological caspase-8 and -3 substrate, correlated with procaspase-8 processing in both scenarios (Figure 5c ). When suppressing procaspase-8 expression by siRNA transfection (Figure 5d, Supplementary  Figure 8C ), DEVDase activity in response to proteasome inhibition was significantly reduced (Figure 5e ). Likewise, time-lapse imaging indicated that procaspase-8 but not procaspase-3 depletion massively reduced the percentage of cells displaying DEVDase activity (Figure 5f ). Furthermore, procaspase-3 processing into p20/p19 subunits and cell death were reduced upon procaspase-8 silencing (Figure 5g and h). These data therefore indicate that in response to proteasome inhibition, caspase-8 serves as the apical caspase in MOMP-impaired cells.
Caspase-8 activation requires the dimerisation and autocatalytic processing of procaspase-8, 20 and Fas-associated death domain (FADD) is the essential recruitment protein for procaspase-8 dimerisation. Depleting FADD in HeLa-Bcl-2 cells (Figure 5i, Supplementary Figure 8D ) resulted in significantly reduced DEVDase activity in response to proteasome inhibition (Figure 5j) . In control experiments, depletion of caspase-8 and FADD was sufficient to impair death receptor-mediated apoptosis in HeLa cells (Supplementary Figure 4) , showing that the siRNAs used also conferred protection in a canonical apoptosis signalling model. Our results therefore indicate that the MOMPindependent, mild DEVDase activity detected in response to proteasome inhibition arises from FADD-dependent caspase-8 activation.
Apical caspase-8 activation is independent of death receptor ligands. We next investigated whether canonical death receptor pathways are required to establish apical caspase-8 activity. Proteasome inhibition may induce the secretion of death receptor ligands such as TRAIL, tumour necrosis factor-a (TNF-a) or fas ligand (FasL), which may in turn activate caspase-8 by autocrine death receptor activation. Pretreatment of parental HeLa cells with death receptor-neutralising antibodies fully blocked caspase-3 processing following TRAIL, TNF-a or FasL exposure (Figure 6a) . Pretreatment of HeLa-Bcl-2 cells with the receptor-neutralising antibodies alone or in combination, however, did not affect bortezomib-induced residual procaspase-3 processing (Figure 6b and c) . These data therefore indicate independence of autocrine death ligand signalling.
Proteasome inhibition induces autophagy, which contributes to caspase-8 processing and cell death. Autophagy can increase as a compensatory means of protein degradation when the proteasomal pathway is blocked. 21 Furthermore, in proliferating T cells caspase-8, in complex with FADD and receptor-interacting serine/ threonine-protein kinase 1 (RIPK1), was found activated on autophagosomal membranes. 22 We therefore investigated whether a link between autophagic signalling, caspase-8 processing and cell death could be observed in response to proteasome inhibition.
Autophagic flux increased in HeLa Bcl-2 cells following bortezomib exposure, as evidenced by the accumulation of autophagy marker protein LC3 and the accumulation of lipidated LC3-II when inhibiting lysosomal proteases using E64 D and pepstatin A (Figure 7a) . Accordingly, the amounts of p62, an autophagy adaptor protein and indicator of protein aggregation that accumulates upon proteasome inhibition, increased following bortezomib treatment (Figure 7a and b) , and a further increase, indicative of elevated autophagic flux, was found upon E64 D/pepstatin A addition (Figure 7a ). The levels of FADD also accumulated strongly, whereas increases in RIPK1 were modest and transient (Figure 7b ). RIPK1 is a physiological substrate of caspase-8, and its late loss was prevented by zVAD-fmk (not shown). Autophagy induction was also detected when expressing a mCherry-GFP-LC3 fusion protein. The number of GFP-positive punctae, representing autophagosomes, increased strongly in response to bortezomib (Figure 7c ). The GFP fluorescence is quenched upon fusion of autophagosomes with lysosomes, whereas mCherry fluorescence persists. 23 The number and intensities of mCherry punctae were higher than the GFP signals (Figure 7c) , indicating an increase in autolysosomes and overall autophagic flux.
Autophagy induction was linked to caspase-8 activation, as 3-methyl adenine (3-MA), an inhibitor of autophagosome formation, but not necrostatin, an inhibitor of RIPK1, reduced procaspase-8 processing (Figure 7d ). LC3-I to LC3-II conversion was noticeably impaired, confirming autophagy inhibition in 3-MA/bortezomib co-treatments (Figure 7d ). When investigating whether autophagy inhibition by 3-MA also reduced the overall amount of cell death following bortezomib addition, we observed a mild but nevertheless significant protection (Figure 7e ). RIPK1 inhibition did not reduce cell death (Figure 7e ), suggesting that necroptosis or excessive autophagy arising from RIPK1 activities [24] [25] did not contribute to cell death. The reduction in cell death might appear rather modest; however, as 3-MA potently induced apoptosis in HeLa cells (Supplementary Figure 6A) , and as cell death of HeLa Bcl-2 cells upon bortezomib/3-MA co-treatments was z-VAD-fmk sensitive (Supplementary Figure 6B) , it is likely that an alternative form of caspasedependent death, which we do not further characterise here, is synergistically promoted at these conditions.
Given the above results, we next also blocked autophagy more specifically by depleting Atg5. Atg5 is essential for autophagosome formation, is found conjugated to Atg12 and it was shown that caspase-8 activation during T-cell proliferation requires the FADD-dependent docking to Atg5-Atg12 on autophagosomes. 22 Indeed, depleting HeLa-Bcl-2 cells of Atg5 expression blocked caspase-8 processing in response to bortezomib (Figure 7f ) and significantly reduced cell death (Figure 7g ). Our data therefore show that caspase-8 processing is strongly impaired when inhibiting autophagy pharmacologically or by Atg5 depletion, indicating that autophagosome formation is an important contributor to caspase-8 activation following proteasome inhibition.
XIAP depletion and Smac-derived peptides enhance proteasome inhibitor-induced apoptosis in Bcl-2-overexpressing cells. Most cells require the mitochondrial pathway to execute apoptosis. In MOMP-impaired cells, XIAP prevents caspase-8-mediated caspase-3 activation in response to death ligands. 26 We therefore hypothesised that DEVDase activity evoked by proteasome inhibition could be enhanced by XIAP depletion or by XIAP-antagonising Smac peptides. XIAP depletion (Figure 8a, Supplementary Figure  8E ) indeed significantly enhanced DEVD probe cleavage and increased cell death (Figure 8b and c) . To circumvent the requirement for transfection procedures, we also synthesised a XIAP-antagonising peptide (AVPIA) fused to an HIVderived import sequence. 27 Control measurements in HeLa-Bcl-2 and H460-Bcl-2 cells indicated that the peptide alone did not evoke noticeable cell death (Figure 8d and e) , nor did it enhance STS-induced death (Supplementary Figure 7) . AVPIA peptide/bortezomib co-treatments, however, markedly enhanced apoptosis in HeLa-Bcl-2 and H460-Bcl-2 cells (Figure 8d and e) , indicating that antagonising XIAP is a promising approach to overcome the apoptosis resistance of MOMP-impaired human cancer cells.
Discussion
We identified that proteasome inhibition promotes the FADDdependent activation of caspase-8 in human cancer cells in which the mitochondrial apoptosis pathway is blocked, and that autophagy induction contributes to caspase-8 activation. Caspase-8 activity is low and persistent, without leading to immediate apoptosis. Cellular commitment to apoptosis can be promoted by antagonising XIAP. This provides a strategy to restore the susceptibility of highly resistant human cancer cells that cannot execute apoptosis via the mitochondrial pathway. Proteasome inhibition affects the relative abundance of hundreds of cellular proteins and is believed to induce apoptosis mainly through the mitochondrial pathway by the accumulation of BH3-only proteins. We showed that in cells in which the mitochondrial apoptosis pathway is blocked, caspase-8 can be activated in response to proteasome inhibition, and that this was the predominant response in the majority of cells investigated. Although previous studies already suggested a role for caspase-8 in apoptosis following proteasome inhibition, [28] [29] time-lapse and single-cell analyses here unequivocally showed that caspase-8 acts as the apical caspase in this treatment paradigm rather than being All experiments were repeated at least once and similar results were obtained processed subsequent to caspase-3, which has largely overlapping substrate specificities. 18 Canonical activation of caspase-8 requires the dimerisation and autocatalytic processing at multiprotein platforms, such as the DISC during extrinsic apoptosis. 20, 30 We here showed that autophagy induction contributes significantly to FADDdependent caspase-8 activation. A link between autophagy, FADD and caspase-8 activation was indeed reported previously during T-cell expansion and cell cycle progression, 22, 31 indicating that basal autophagy in proliferating T cells may establish low caspase-8 activities. Of note, autophagy and caspase-8 activity in these scenarios are physiologically required for cell proliferation rather than inducing death. 22, 25, 31 Protein degradation might quickly remove or restrict naturally occurring, sublethal caspase-8 activities in these cells. Proteasome inhibition instead, apart from enhancing caspase-8 activation through inducing autophagy, additionally may cause an abnormal accumulation of active caspase-8 through blocking protein degradation. This would likely contribute to rendering autophagy-dependent caspase-8 activation to become potentially lethal.
Mechanistically, it was shown that caspase-8 and FADD can bind to Atg5/Atg12 clusters on autophagosomal membranes, 22 which could promote caspase-8 activation through induced proximity. The necroptosis inducer and caspase-8 substrate RIPK1 is part of these complexes; however, we could not find that RIPK1 activity contributed to death. This is consistent with the notion that RIPK1 only induces autophagydependent necroptosis when caspase-8 is absent. 22 The late and zVAD-fmk-sensitive loss in RIPK1 observed in our experiments indeed rather suggests that caspase-8 activation upon proteasome inhibition may actively suppress necroptotic responses.
We cannot rule out that apart from autophagosomes, additional scaffolds for caspase-8 activation are formed upon proteasome inhibition. Although we excluded that extrinsic stimulation of death receptors contributed to caspase-8 activation, it was shown that impaired protein degradation can induce an abnormal accumulation of high-turnover death receptors. 32 This may result in artificial death receptor oligomerisation and caspase-8 activation also in the absence of death ligands. Caro-Maldonado et al. 33 showed that MOMP-impaired cells can activate caspase-8 independent of death receptors following glucose deprivation by an as of yet unresolved mechanism. As proteasomal protein degradation is highly energy-dependent, lack of sufficient ATP as a consequence of glucose deprivation might promote autophagy and caspase-8 activation in a manner related to our observations.
As most proapoptotic chemotherapeutics induce death via the mitochondrial pathway, elevated expression of antiapoptotic Bcl-2 family members poses a significant challenge to the development of efficient anticancer therapies. This is of clinical relevance as the expression of Bcl-2, Bcl-xL or Mcl-1 has been associated with poor prognosis or increased risk of recurrence in various cancers, including chronic lymphocytic leukaemia, follicular lymphoma and breast cancer. [34] [35] [36] Although Bcl-2-inhibiting compounds are currently in preclinical and clinical trials, no single compound is sufficient to antagonise all antiapoptotic family members with high efficiency or without significant off-target effects. 37 The direct activation of executioner caspases by caspase-8 offers the possibility to bypass the requirement for MOMP, but in most cells is significantly impaired by the presence of XIAP, a major regulator of the caspase-8/-3 axis. 26, 38 We showed that the death ligand-independent apical caspase-8 activation upon proteasome inhibition can be exploited to execute apoptosis in otherwise highly resistant Bcl-2-overexpressing cells when XIAP is antagonised. This may provide a new and attractive strategy to induce death in cancer cells that otherwise do not respond to proapoptotic chemotherapeutics.
